BioSpace News Archive

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 11th Annual Biotech Symposium:

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference

Histogen Inc. (NASDAQ: HSTO), today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021.

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at two upcoming virtual investor conferences.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell announced that the New Drug Application for TV-46000/mdc-IRM for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration.

Novanta Inc., a trusted technology partner to medical and advanced technology equipment manufacturers, announced that it has completed the acquisitions of Schneider Electric Motion USA Inc. and ATI Industrial Automation Inc..

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 80,000 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

Biocept, a leading provider of molecular diagnostic assays and services, announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.